VisionCare’s implantable telescope
This article was originally published in The Gray Sheet
Executive Summary
VisionCare Ophthalmic Technologies begins enrollment of a multi-center Phase II/III clinical trial of its IMT implantable miniature telescope. The pea-sized device is implanted in the eye under local anesthesia to provide magnification of 3.0x or 2.2x to aid patients with moderate to severe bilateral central vision impairment due to either dry or scar-stage wet age-related macular degeneration or Stargardt's macular dystrophy. The pivotal study will include about 200 patients at up to 30 U.S. sites...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.